Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968446 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Vitamin D After Application With Valchlor
A Early Phase 1 study, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 33
- Enrollment target
NCT02968446: Completed Early Phase 1 study, sponsored by University Hospitals Cleveland Medical Center.
NCT02968446 is a Early Phase 1 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 33 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02968446, a Early Phase 1 study, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the effects of an oral Vitamin D on the body's immune system. An interest has been growing because studies have shown that Vitamin D may reduce inflammation and harmful effects in the body, however, the best dose for Vitamin D is still unknown. Inflammation is the body's physical response to infection, injury, or long term disease. Pain, redness, heat, and sometimes loss of function are all signs of inflammation in the body. This study will look at product use, testing skin irritation in healthy volunteers and seeing how Vitamin D may help stop or reduce inflammation and skin irritation, which could one day help doctors prescribe Vitamin D to patients with long term disease to relieve their symptoms.
Primary Outcome
Skin erythema (redness) will be quantified using a CR300 chromameter. The difference in erythema between exposed and non-exposed skin will be calculated after valchlor exposure
Interventions
- DRUG Valchlor
- DIETARY_SUPPLEMENT 4 placebo
- DIETARY_SUPPLEMENT 4 Vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-11-17 |
| Est. Completion | 2018-10-01 |
| Phase | Early Phase 1 |
What the finished NCT02968446 record still lists
NCT02968446 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 3 interventions - of which Valchlor is the first listed.
NCT02968446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02968446 about?
NCT02968446 is a clinical study titled "Effect of Vitamin D After Application With Valchlor". The purpose of this research study is to evaluate the effects of an oral Vitamin D on the body's immune system. An interest has been growing because studies have shown that Vitamin D may reduce inflammation and harmful effects in the body, however, the best dose for Vitamin D is still unknown. Inf...
What is the current status of trial NCT02968446?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 33 participants. The study started on 2016-11-17. Estimated completion is 2018-10-01.
What interventions are being tested in trial NCT02968446?
The interventions under investigation include: Valchlor (DRUG), 4 placebo (DIETARY_SUPPLEMENT), 4 Vitamin D (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02968446?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02968446's enrollment target sits among peer trials
33 763rd of 2000 higher than 1,227 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI